Cholesterol and beyond - The role of the mevalonate pathway in cancer biology.
Antineoplastic Agents
/ pharmacology
Cell Proliferation
Cell Transformation, Neoplastic
/ drug effects
Cholesterol
/ biosynthesis
Clinical Trials as Topic
Disease Progression
Geranyltranstransferase
/ antagonists & inhibitors
Humans
Hydroxymethylglutaryl CoA Reductases
/ metabolism
Metabolic Networks and Pathways
/ drug effects
Mevalonic Acid
/ metabolism
Neoplasms
/ drug therapy
Protein Processing, Post-Translational
/ drug effects
Sterol Regulatory Element Binding Proteins
/ antagonists & inhibitors
Treatment Outcome
rho GTP-Binding Proteins
/ metabolism
Amino-bisphosphonates
Cancer biology
Cholesterol
Mevalonate pathway
Statins
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
25
10
2019
revised:
14
01
2020
accepted:
30
01
2020
pubmed:
3
2
2020
medline:
22
7
2020
entrez:
3
2
2020
Statut:
ppublish
Résumé
Cancer is a multifaceted global disease. Transformation of a normal to a malignant cell takes several steps, including somatic mutations, epigenetic alterations, metabolic reprogramming and loss of cell growth control. Recently, the mevalonate pathway has emerged as a crucial regulator of tumor biology and a potential therapeutic target. This pathway controls cholesterol production and posttranslational modifications of Rho-GTPases, both of which are linked to several key steps of tumor progression. Inhibitors of the mevalonate pathway induce pleiotropic antitumor-effects in several human malignancies, identifying the pathway as an attractive candidate for novel therapies. In this review, we will provide an overview about the role and regulation of the mevalonate pathway in certain aspects of cancer initiation and progression and its potential for therapeutic intervention in oncology.
Identifiants
pubmed: 32007596
pii: S0304-419X(19)30174-X
doi: 10.1016/j.bbcan.2020.188351
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Sterol Regulatory Element Binding Proteins
0
Cholesterol
97C5T2UQ7J
HMGCR protein, human
EC 1.1.1.-
Hydroxymethylglutaryl CoA Reductases
EC 1.1.1.-
Geranyltranstransferase
EC 2.5.1.10
rho GTP-Binding Proteins
EC 3.6.5.2
Mevalonic Acid
S5UOB36OCZ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188351Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors have received grants or honorarium for advisory boards or lectures to the individual or the institution by Amgen (MR, LCH, TDR), Biomedica (AG), Novartis (LCH, TDR), and Merck (LCH, TDR).